Ayass BioScience, LLC was established in 2014 with a mission to provide early disease detection, develop a disease monitoring system, and ultimately achieve better patient outcome by implementing Molecular Modern Medicine to daily clinical practice. We emphasize on Pathophysiology, Genetic, Epigenetic, and Proteomic/Metabolic profiling by conducting comprehensive immunologic testing, and next generation sequencing. Data collection and, more importantly, data interpretation through our bioinformatics and biostatistics department provides meaningful molecular analysis that guides precision medical practices. Our research in the field of Aptamers has opened the door to ground-breaking technology in the fields of both diagnostics and therapeutics. In the ever-evolving landscape of biotechnology and genomics, our company stands out as a trailblazer in the field of Transcriptome AI Analysis. With a relentless commitment to innovation, cutting-edge technology, and a team of brilliant scientists, our F420 program is redefining the way we understand gene expression and regulation. Our pioneering transcriptome AI analysis has ushered in a new era of genomic insights, propelling scientific discovery and innovation to unprecedented heights. Through single-cell resolution, long-read sequencing, dynamic expression profiling, integrative systems biology, and AI-powered insights, F420 program continues to empower us with the tools we need to unravel the mysteries of gene expression and revolutionize our understanding of many health conditions. Our goal is to help clinicians implement unique precision medicine in their daily practice.
